In general, a majority of voters just don’t like the DOGE czar at all. According to Hart Research, 54 percent of voters had ...

Donald Trump is continuing to push his crazy plan for the United States to take over Gaza, even after the idea was soundly ...

One of Robert F. Kennedy Jr.’s most devoted cheerleaders, Dr. Patrick Soon-Shiong, the billionaire owner of the Los Angeles ...

California-based ImmunityBio has entered into a collaboration and supply agreement with Sino-American biotech BeiGene (to be ...

ImmunityBio will part with 10 employees this quarter. Last fall, it cut 31 employees. The moves come as the biotech works to ...

Energy equipment manufacturer GE Vernova saw its share prices grow by 8.42 percent on Thursday to close at $382.94 apiece as ...

We recently compiled a list of the 12 Stocks That Will Double in 2025. In this article, we are going to take a look at where ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

In this article, we will take a look at the 12 stocks that will double in 2025.

The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.

Nancy Ghattas, VP, US franchise head, imunno-oncology, gastrointestinal tumors, AstraZeneca, discusses the promising results from the ADRIATIC trial, in which patients were treated with Imfinzi for ...

ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...